Dyslipidaemia and hepatic steatosis: mechanisms and implications for lipid-lowering therapy.

Averna M, Hussain MM, Norata GD

Open source

DOI
10.1038/s41569-026-01336-1
Published
2026 Aug 27
Container
Nature reviews. Cardiology
Publisher
Not recorded
Open access
no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1038/s41569-026-01336-1,
  title = {Dyslipidaemia and hepatic steatosis: mechanisms and implications for lipid-lowering therapy.},
  author = {Averna M and Hussain MM and Norata GD},
  year = {2026},
  journal = {Nature reviews. Cardiology},
  doi = {10.1038/s41569-026-01336-1},
  url = {https://doi.org/10.1038/s41569-026-01336-1}
}

RIS

TY  - JOUR
TI  - Dyslipidaemia and hepatic steatosis: mechanisms and implications for lipid-lowering therapy.
AU  - Averna M
AU  - Hussain MM
AU  - Norata GD
PY  - 2026
JO  - Nature reviews. Cardiology
DO  - 10.1038/s41569-026-01336-1
UR  - https://doi.org/10.1038/s41569-026-01336-1
ER  - 

APA

M, A., MM, H., & GD, N. (2026). Dyslipidaemia and hepatic steatosis: mechanisms and implications for lipid-lowering therapy.. Nature reviews. Cardiology. https://doi.org/10.1038/s41569-026-01336-1

Source records